Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, Bellinvia A, Tudisco L, Fratangelo R, Comi G, Patti F, De Luca G, Brescia Morra V, Cocco E, Pozzilli C, Sola P, Bergamaschi R, Salemi G, Inglese M, Millefiorini E, Galgani S, Zaffaroni M, Ghezzi A, Salvetti M, Lus G, Florio C, Totaro R, Granella F, Vianello M, Gatto M, Di Battista G, Aguglia U, Logullo FO, Simone M, Lucisano G, Iaffaldano P, Trojano M. Amato MP, et al. Among authors: galgani s. Brain. 2020 Oct 1;143(10):3013-3024. doi: 10.1093/brain/awaa251. Brain. 2020. PMID: 32935843
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C. Prosperini L, et al. Among authors: galgani s. J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22. J Neurol. 2017. PMID: 27878443
Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register.
Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Italian Multiple Sclerosis Register Centers Group, the Scientific Committee of Italian SM Register. Lepore V, et al. Eur J Neurol. 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589. Epub 2020 Nov 6. Eur J Neurol. 2021. PMID: 33058344
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Iaffaldano P, Lucisano G, Patti F, Brescia Morra V, De Luca G, Lugaresi A, Zaffaroni M, Inglese M, Salemi G, Cocco E, Conte A, Ferraro D, Galgani S, Bergamaschi R, Pozzilli C, Salvetti M, Lus G, Rovaris M, Maniscalco GT, Logullo FO, Paolicelli D, Achille M, Marrazzo G, Lovato V, Comi G, Filippi M, Amato MP, Trojano M; Italian MS Register. Iaffaldano P, et al. Among authors: galgani s. Mult Scler. 2021 Mar;27(3):430-438. doi: 10.1177/1352458520974366. Epub 2020 Nov 19. Mult Scler. 2021. PMID: 33210986
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register.
D'Amico E, Zanghì A, Romeo M, Cocco E, Maniscalco GT, Brescia Morra V, Paolicelli D, De Luca G, Galgani S, Amato MP, Salemi G, Inglese M, Confalonieri PA, Lus G, Avolio C, Gallo A, Vianello M, Onofrj M, Filippi M, Trojano M, Patti F. D'Amico E, et al. Among authors: galgani s. Neurotherapeutics. 2021 Apr;18(2):905-919. doi: 10.1007/s13311-020-01001-6. Epub 2021 Feb 2. Neurotherapeutics. 2021. PMID: 33528815 Free PMC article.
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
Chisari CG, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M, Brescia Morra V, Cocco E, Marfia GA, Grimaldi LM, Inglese M, Bonavita S, Lugaresi A, Salemi G, De Luca G, Cottone S, Conte A, Sola P, Aguglia U, Maniscalco GT, Gasperini C, Ferrò MT, Pesci I, Amato MP, Rovaris M, Solaro C, Lus G, Maimone D, Bergamaschi R, Granella F, Di Sapio A, Bertolotto A, Totaro R, Vianello M, Cavalla P, Bellantonio P, Lepore V, Patti F; Italian MS Register Study Group.. Chisari CG, et al. J Neurol. 2022 Feb;269(2):933-944. doi: 10.1007/s00415-021-10676-6. Epub 2021 Jun 28. J Neurol. 2022. PMID: 34181077
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
Portaccio E, Fonderico M, Iaffaldano P, Pastò L, Razzolini L, Bellinvia A, De Luca G, Ragonese P, Patti F, Brescia Morra V, Cocco E, Sola P, Inglese M, Lus G, Pozzilli C, Maimone D, Lugaresi A, Gazzola P, Comi G, Pesci I, Spitaleri D, Rezzonico M, Vianello M, Avolio C, Logullo FO, Granella F, Salvetti M, Zaffaroni M, Lucisano G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register Centers Group. Portaccio E, et al. JAMA Neurol. 2022 Sep 1;79(9):869-878. doi: 10.1001/jamaneurol.2022.1929. JAMA Neurol. 2022. PMID: 35877104 Free PMC article. Clinical Trial.
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
Ferraro D, Iaffaldano P, Guerra T, Inglese M, Capobianco M, Brescia Morra V, Zaffaroni M, Mirabella M, Lus G, Patti F, Cavalla P, Cellerino M, Malucchi S, Pisano E, Vitetta F, Paolicelli D, Sola P, Trojano M; Italian MS Register. Ferraro D, et al. J Neurol. 2022 Mar;269(3):1463-1469. doi: 10.1007/s00415-021-10708-1. Epub 2021 Jul 22. J Neurol. 2022. PMID: 34292396
From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
Prosperini L, Mancinelli CR, Pozzilli C, Grasso MG, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, Buttari F, Centonze D, Di Battista G, Frisullo G, Galgani S, Gasperini C. Prosperini L, et al. Among authors: galgani s. Eur Neurol. 2014;71(5-6):233-41. doi: 10.1159/000356786. Epub 2014 Jan 25. Eur Neurol. 2014. PMID: 24480868
95 results